重症新型冠状病毒肺炎在体外膜氧合期间抗凝管理的研究进展

Research progress of anticoagulation management of severe COVID-19 during extracorporeal membrane oxygenation

新型冠状病毒肺炎(COVID-19)是由严重急性呼吸综合征冠状病毒2型(SARS-CoV2)引起的全球性、流行性疾病,部分重症患者需采用体外膜氧合(ECMO)治疗。重症COVID-19患者易出现严重凝血功能障碍,合并ECMO治疗时会进一步增加抗凝管理的难度。因此本文总结重症COVID-19患者凝血功能变化及在ECMO期间的抗凝管理,旨在为临床提供更好的治疗指导。

Coronavirus disease 2019(COVID-19)is a global epidemic disease caused by severe acute respiratory syndrome coronavirus type 2(SARS-CoV2).Some severe patients need to be treated with extracorporeal membrane oxygenation(ECMO).Se⁃vere COVID-19 patients are prone to severe coagulation dysfunction,and ECMO treatment will further increase the difficulty of antico⁃agulation management.Therefore,this study summarizes the changes of blood coagulation function and anticoagulation management dur⁃ing ECMO in patients with severe COVID-19,in order to provide better treatment guidance for clinic.